Search:   [Advanced]

Showing drug card for Polystyrene sulfonate (DB01344)

Legend: drug field target field enzyme field

for All Approved Biotech Experimental Illicit Nutraceutical Small Molecule Withdrawn drugs

Version	2.5
Creation Date	2007-06-30 18:12:41
Update Date	2009-06-23 18:08:25
Primary Accession Number	DB01344
Secondary Accession Number	Not Available
Name	Polystyrene sulfonate
Drug Type	Approved Small Molecule
Description	Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, HIV. [Wikipedia]
Synonyms	Polystyrene sulfonic acid SPS Sodium polystyrene sulfonate Sodium polystyrene sulfonic acid
Brand Names	Kayexalate Kionex
Brand Mixtures	Not Available
Chemical IUPAC Name	calcium 2-ethenylbenzenesulfonate
Chemical Formula	C8H7CaO3S
Chemical Structure
CAS Registry Number	28210-41-5
InChI Identifier	InChI=1/C8H8O3S.Ca/c1-2-7-5-3-4-6-8(7)12(9,10)11;/h2-6H,1H2,(H,9,10,11);/q;+2/p-1/fC8H7O3S.Ca/q-1;m
InChI Key	IJBYVKWTVVYTPL-BCXMUDFPCP
KEGG Drug	Not Available
KEGG Compound	Not Available
PubChem Compound	169893
PubChem Substance	747421
ChEBI ID	Not Available
PharmGKB ID	Not Available
HET ID	Not Available
GenBank ID	Not Available
Drug ID Number [DIN]	Not Available
RxList Link	Not Available
PDRhealth Link	Not Available
Wikipedia Link	http://en.wikipedia.org/wiki/Polystyrene_sulfonate
FDA Label	Not Available
Material Safety Data Sheet (MSDS)	Not Available
Synthesis Reference	Not Available
Average Molecular Weight	223.2820
Monoisotopic Molecular Weight	222.9742
State	Solid
Melting Point	Not Available
Experimental Water Solubility	Not Available Source: PhysProp
Predicted Water Solubility	2.59e-01 mg/mL Calculated using ALOGPS
Experimental LogP/Hydrophobicity	Not Available Source: PhysProp
Predicted LogP	2.05 Calculated using ALOGPS
Experimental LogS	Not Available
Predicted LogS	-3.00 Calculated using ALOGPS
Experimental Caco2 Permeability	Not Available
pKa/Isoelectric Point	Not Available
Mass Spectrum	Not Available
MOL File	Show | Download
SDF File	Show | Download
PDB File	Show | Download
2D Structure
3D Structure
Experimental PDB ID	Not Available
Isomeric SMILES	[Ca++].[O-]S(=O)(=O)C1=CC=CC=C1C=C
Canonical SMILES	[Ca++].[O-]S(=O)(=O)C1=CC=CC=C1C=C
Drug Category	Not Available
ATC Codes	Not Available
AHFS Codes	Not Available
Indication	Used to treat abnormally high potassium levels.
Pharmacology	Polystyrene sulfonate affects the exchange of sodium and potassium in the body. Polystyrene sulfonate is used to treat high levels of potassium in the blood, also called hyperkalemia. It is a potassium-binding ion-exchange resin that can be administered orally (25 grams in 20% sorbitol) or rectally (50 grams in 20% sorbitol).
Mechanism of Action	Polystyrene sulfonate, which is not absorbed, binds excess potassium, carrying it out of the body.
Absorption	Not absorbed following oral administration.
Toxicity	Overdose symptoms may include confusion, irritability, trouble thinking or concentrating, muscle weakness, or trouble breathing.
Protein Binding	Not Available
Biotransformation	Not Available
Half Life	Not Available
Dosage Forms	Form Route Enema Rectal Liquid Oral
Patient Information	Not Available
Contraindications	Not Available
Interactions	Not Available
Drug Interactions	Drug Interaction Aluminium Risk of alkalosis in renal impairment Amiloride Risk of alkalosis in renal impairment Bismuth Risk of alkalosis in renal impairment Calcium Risk of alkalosis in renal impairment Eplerenone Risk of alkalosis in renal impairment Magnesium Risk of alkalosis in renal impairment Potassium Risk of alkalosis in renal impairment Spironolactone Risk of alkalosis in renal impairment Triamterene Antagonism of action Triamterene Antagonism of action
Food Interactions	Avoid calcium, magnesium and potassium. Take on an empty stomach.
Pathways	Not Available
General References	Wikipedia
Organisms Affected	Humans and other mammals

This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community.